Roconkibart clinical trials
Also written JS005.
How each study uses roconkibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 6
Studies
Open first, then newest update. How each study uses roconkibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy VolunteersCompletedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT04220073Written as JS005 (recombinant humanized monoclonal antibody against IL-17A)
- Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active ASCompletedPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT05212051Written as JS005
- Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpATerminatedPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT05242588Written as JS005
- A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injectorCompletedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT06732973Written as JS005
- A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT05975268Written as JS005 (recombinant humanized monoclonal antibody against IL-17A)
- Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple DosingCompletedPhase 1/2Shanghai Junshi Bioscience Co., Ltd.NCT05344248Written as JS005 (recombinant humanized monoclonal antibody against IL-17A)
Codes
What other systems call roconkibart · ClinicalTrials.gg INT017287
- UNII (FDA) MD885NVL3QROCONKIBARTOne source FDA
- NCI Thesaurus C203102RoconkibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MD885NVL3Q | ROCONKIBART | One source FDA |
| NCI Thesaurus | C203102 | Roconkibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.